Autologous EBV Specific CTLs for Prophylaxis and Therapy of EBV Lymphoma Post Solid Organ Transplant.

Trial Profile

Autologous EBV Specific CTLs for Prophylaxis and Therapy of EBV Lymphoma Post Solid Organ Transplant.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Baltaleucel-T (Primary)
  • Indications Epstein-Barr virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms EUCLID
  • Most Recent Events

    • 15 Jun 2015 According to Atara Biotherapeutics media release, data has been presented at the 2015 American Society of Clinical Oncology Annual Meeting.
    • 09 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top